MedTrace Logo

Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

NCT03282643 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2019-04-16

No results posted yet for this study

Summary

The study is designed to compare the efficacy and safety of oral rivaroxaban and subcutaneous low-molecular-weight heparin in preventing femoral venepuncture associated thrombosis among cancer patients.

Conditions

  • Neoplasms

Interventions

DRUG

Rivaroxaban 10 MG

Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture

DRUG

Rivaroxaban 20 MG

Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture

DRUG

Low-molecular-weight heparin

0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)

Sponsors & Collaborators

  • Capital Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-16
Primary Completion
2018-06-30
Completion
2019-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03282643 on ClinicalTrials.gov